source
- Expert outlines sequencing strategies for relapsed/refractory multiple myeloma amid rise of T-cell redirecting therapiesDr. Diana Cirstea, a specialist in multiple myeloma, explained how treatment sequencing is evolving for patients with relapsed or refractory disease. She highlighted that the growing availability o…
- Pembrolizumab with BCG shows 92% 6-month complete response in very high-risk T1 bladder cancerA clinical study evaluated the combination of pembrolizumab and bacillus Calmette-Guérin (BCG) in patients with very high-risk T1 non-muscle invasive bladder cancer who had not previously received…